Representing uncertainty: The role of cost-effectiveness acceptability curves

被引:823
作者
Fenwick, E [1 ]
Claxton, K
Sculpher, M
机构
[1] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England
[2] Univ York, Dept Econ & Related Studies, York YO1 5DD, N Yorkshire, England
关键词
cost-effectiveness acceptability curves; cost-effectiveness acceptability frontiers; decision-making; net benefits; uncertainty;
D O I
10.1002/hec.635
中图分类号
F [经济];
学科分类号
02 ;
摘要
Decision-making in health care is inevitably undertaken in a context of uncertainty concerning the effectiveness and costs of health care interventions and programmes. One method that has been suggested to represent this uncertainty is the cost-effectiveness acceptability curve. This technique, which directly addresses the decision-making problem, has advantages over confidence interval estimation for incremental cost-effectiveness ratios. However, despite these advantages, cost-effectiveness acceptability curves have yet to be widely adopted within the field of economic evaluation of health care technologies. In this paper we consider the relationship between cost-effectiveness acceptability curves and decision-making in health care, suggest the introduction of a new concept more relevant to decision-making, that or the cost-effectiveness frontier. and clarify the use of these techniques when considering decisions involving multiple interventions. We hope that as a result we can encourage the greater use of these techniques. Copyright (C) 2001 John Wiley Sons, Ltd.
引用
收藏
页码:779 / 787
页数:9
相关论文
共 21 条
[1]  
[Anonymous], IMPROVING EFFICIENCY
[2]  
Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO
[3]  
2-F
[4]  
BRIGGS A, 1999, HLTH TECHNOL ASSESS, V3
[5]  
Briggs AH, 1999, HEALTH ECON, V8, P257, DOI 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO
[6]  
2-E
[7]  
Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO
[8]  
2-9
[9]   The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies [J].
Claxton, K .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) :341-364
[10]   Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) [J].
Gray, A ;
Raikou, M ;
McGuire, A ;
Fenn, P ;
Stevens, R ;
Cull, C ;
Stratton, I ;
Adler, A ;
Holman, R ;
Turner, R .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7246) :1373-1378